TL;DR
This paper addresses the critical need for accurate measurement of nasal antibodies against SARS-CoV-2, which are crucial for preventing infection and transmission. The authors demonstrate that existing serum-based standards are unsuitable for nasal antibody assessment due to differences in antibody composition. They successfully developed and validated a new national standard (CS2) derived from nasal mucosal lining fluids, significantly improving inter-laboratory consistency and enabling more reliable evaluation of mucosal vaccines.
What Problem Does This Paper Address?
Respiratory viruses like SARS-CoV-2 pose a significant global health threat. While vaccines have been instrumental in reducing severe disease, they have shown limited efficacy in preventing infection and transmission, particularly with the emergence of new variants like Omicron. This is largely because current vaccines primarily induce systemic immunity, while the initial site of infection and transmission for these viruses is the upper respiratory tract. Mucosal immunity, specifically antibodies present in nasal secretions (nasal antibodies), plays a vital role in blocking viral entry and spread at this site.
However, a major challenge in studying and evaluating mucosal immunity has been the lack of appropriate reference standards. Existing standards for antibody assessment are typically derived from blood serum, which contains different types and forms of antibodies (primarily monomeric IgG and IgA) compared to nasal secretions (predominantly dimeric or polymeric secretory IgA, sIgA). This mismatch means that serum-based standards are not directly applicable or validated for measuring nasal antibodies, leading to potential inaccuracies and inconsistencies in research and vaccine development. The paper aims to bridge this gap by developing and validating a reliable standard for human nasal antibody measurements against SARS-CoV-2.
Methods
The researchers employed a multi-pronged approach to tackle the problem:
- Immunoglobulin (Ig) Composition Analysis: They used Western blot (WB) to characterize the types and forms of immunoglobulins present in both nasal mucosal lining fluids (NMLFs) and serum samples. This was crucial to highlight the inherent differences that make serum standards problematic.
- Serum Standard Applicability Assessment: They conducted experiments using electrochemiluminescent (ECL) assays to evaluate how well serum-derived standards performed when used to quantify nasal antibodies. This involved comparing dose-response curves and assessing the impact of using a "heterologous" (serum) standard on nasal samples.
- Development of Candidate Standards (CSs):
- CS1 and CS2: These were developed using NMLFs collected from individuals who had recovered from SARS-CoV-2 infection or received intranasal vaccines. CS1 was a liquid pool, while CS2 was a freeze-dried preparation.
- CS3: This was prepared using a highly potent sIgA monoclonal antibody (mAb) with broad binding activity against SARS-CoV-2 variants.
- Collaborative Study: A key part of the validation involved a collaborative study with seven independent laboratories. These labs used various assays (ELISA and ECL) to test coded samples, including the candidate standards and unknown samples. This allowed for the assessment of inter-laboratory variability.
- Statistical Analysis: Rigorous statistical methods were used, including:
- Parallel line analysis and sigmoidal curve modeling: To estimate antibody potency.
- Geometric coefficients of variation (GCV): To measure variability between assays and laboratories.
- Lin's concordance correlation coefficients: To assess agreement between laboratories.
- Regression analysis with 95% prediction intervals: To evaluate the commutability of the standards.
- Stability Studies: The real-time and accelerated stability of the candidate standards were assessed under various temperature and storage conditions to ensure their reliability over time.
Datasets
The study utilized the following:
- Nasal Mucosal Lining Fluids (NMLFs): Collected from 18 healthy donors who had recovered from SARS-CoV-2 infection or received intranasal vaccines. These were used to prepare candidate standards CS1 and CS2.
- Human Serum Samples: Used for comparative analysis of Ig composition and as a potential (but ultimately unsuitable) standard.
- SARS-CoV-2 Variants: The binding activity of the candidate standards was tested against multiple SARS-CoV-2 strains, including WT, Omicron subvariants (e.g., XBB.1.5, EG.5, JN.1), and others.
- Coded Samples: A panel of ten samples was used in the collaborative study, including the candidate standards and unknown samples, to assess inter-laboratory performance.
- Native Human Nasal Samples: 30 samples were used for commutability assessment.
No new benchmark datasets were explicitly introduced, but the study established a new national standard which can serve as a benchmark for future studies.
Key Insights and Ideas
- The "Mucosal-Serum Divide": The most significant insight is the clear demonstration that serum-based standards are fundamentally unsuitable for measuring nasal antibodies due to fundamental differences in Ig composition (monomeric vs. dimeric/polymeric sIgA) and function. This is a critical realization for the field.
- Systematic Error from Heterologous Standards: Using serum standards for nasal antibody assessment introduces substantial systematic errors, potentially leading to over- or underestimation of antibody levels by up to 10-fold. This undermines the reliability of research and vaccine evaluations.
- Nasal Mucosal Lining Fluids as Superior Standards: NMLFs from convalescent or vaccinated individuals are a more appropriate source material for developing nasal antibody standards, as they reflect the actual antibody profile found in the respiratory tract.
- Broad-Spectrum Binding is Key: The chosen national standard (CS2) demonstrated broad binding activity against a wide range of SARS-CoV-2 variants, including the then-emerging Omicron subvariants. This is crucial for a standard to remain relevant as the virus evolves.
- Harmonization is Achievable: The collaborative study proved that a well-characterized nasal standard (CS2) can dramatically improve the consistency and comparability of results across different laboratories and assay methods.
Key Results
- Serum vs. Nasal Ig Composition: Western blot analysis confirmed that nasal sIgA exists predominantly as dimeric/multimeric forms (around 400 kDa), while serum IgA is mostly monomeric (around 160 kDa). Monomeric IgG was present in NMLFs but in small amounts, whereas serum Ig was predominantly monomeric IgG.
- Serum Standard Bias: Using serum standards led to a bias in quantifying nasal samples, with dilution factors causing up to a 3.8-fold difference in measured IgA concentrations. For heterologous serum samples, this bias could be up to 10-fold.
- CS2 as the National Standard: CS2, a freeze-dried NMLF preparation, was selected as the national standard (Lot: 300052-202401, 1000 U/mL) due to its broad binding activity and excellent performance in the collaborative study.
- Inter-Laboratory Variability Reduction: Pre-standardization geometric coefficients of variance (GCV) ranged from 14% to 314%. After standardization with CS2, this variability was significantly reduced to 3-35%.
- Commutability: CS1 and CS2 demonstrated commutability with nasal samples, meaning they behaved similarly to actual nasal samples in different assays. Serum samples, however, showed poor commutability.
- Stability: The freeze-dried CS2 and CS3 showed good real-time and accelerated stability, making them suitable for long-term use as standards.
Limitations and Future Work
- CS2 Usage After Reconstitution: The study noted that CS2, once reconstituted, should be used immediately due to a rapid decrease in potency. This is a practical limitation for laboratory workflows.
- CS1 Stability at Room Temperature: CS1 showed a significant decrease in potency at 25°C, faster than at 37°C, suggesting potential degradation by proteases in the raw material. Further investigation into this phenomenon is needed.
- mAb Standard (CS3) Limitations: While CS3 (mAb-based) showed good binding, its activity against the latest variants like JN.1 was significantly decreased, making it challenging for evaluating newer strains. The authors suggest that a cocktail of multiple mAbs might be more suitable as a reference, but this requires further validation.
- Regulatory Requirements: The authors acknowledge that while their work provides a benchmark for evaluating mucosal vaccines, the data presented cannot yet define regulatory requirements for such vaccines.
- Future Directions: The paper inspires new avenues for developing reference standards for other mucosal vaccines and emphasizes the need for further strengthening of commutability studies for different types of biological reference materials. The establishment of this nasal standard will facilitate more studies on nasal IgA, advancing the understanding of mucosal immunity.
Summary updated